There are significant race and socioeconomic disparities in the use of cardioprotective medications 9 and in health insurance coverage. 10 People of black and Hispanic race consistently report lower rates of statin use. [11] [12] [13] This has been found in both primary prevention 14, 15 and secondary prevention, for example, in patients with peripheral arterial disease. 16 Higher income is associated with increased use of statins, 17 whereas lower educational attainment is associated with reduced initiation of and adherence to cholesterol-lowering therapy. [18] [19] [20] We used data from NHANES 2005 to 2012 to examine how the expansion in statin eligibility under the 2013 ACC/ AHA guidelines affects people of different race and socioeconomic backgrounds, how this relates to health insurance coverage, and how this might affect existing disparities in statin use.
Methods
To make our analysis consistent with prior work, we mirrored the study-sample definition and analytic method of Pencina et al 8 to determine statin eligibility (Methods in the Data Supplement). There are 4 criteria for statin eligibility, 3 of which were changed substantially by the 2013 ACC/AHA guidelines from ATP-III. First, statins were recommended for secondary prevention in all people with established cardiovascular disease, irrespective of their cholesterol levels (ATP-III recommended statins for only those with low-density lipoprotein [LDL] cholesterol ≥100 mg/dL). Second, statins were recommended for people with diabetes mellitus and LDL cholesterol ≥70 mg/dL (as opposed to ≥100 mg/dL under ATP-III). Finally, statins were recommended for all people with LDL cholesterol ≥70 mg/dL and predicted 10-year cardiac risk of ≥7.5%, using the pooled cohort equations (PCE). 21 ATP-III recommended statins for people who had elevated 10-year cardiac risk using several combinations of the Framingham risk score and LDL cholesterol levels. Pencina et al 8 demonstrated that these changes represented a significant expansion in statin eligibility. We further assessed the impact of race and socioeconomic factors on statin eligibility.
Data
The NHANES is a major survey designed to assess the health and nutritional status of adults and children in the United States. The NHANES survey data are publicly available, and their use is approved by the National Center for Health Statistics Ethics Review Board.
We used data collected between 2005 and 2012, from participants between the ages of 40 and 75 for whom fasting data were available. We excluded 130 participants (2.5%) who had triglyceride levels of >400 mg/dL and 55 participants (1.1%) with missing values for LDL cholesterol ( Figure I in the Data Supplement). Analyses on health insurance coverage excluded 3 participants (0.1%) with missing values for insurance coverage. All analyses were conducted using sample weights provided in the fasting subsample to account for the sampling design of NHANES, and the results were extrapolated to the US population.
Statistical Analysis
We assessed eligibility for statin therapy according to the 2004-updated ATP-III criteria and the 2013 ACC/AHA guidelines using the same approach as Pencina et al. 8 Each individual was placed into 1 category based on their indication for statin eligibility in a hierarchical fashion (Data Supplement). We categorized the change in each individual's eligibility status between the ATP-III and the 2013 ACC/ AHA guidelines as no change, not eligible; no change, eligible; became eligible; and lost eligibility. We evaluated change in eligibility according to race, education level, ratio of family income to poverty quartiles, and insurance coverage using χ 2 tests. Individuals were considered to have health insurance if they reported receiving either employer-based, privately purchased, or government-provided insurance. Predicted odds ratios for statin eligibility status compared with no change, not eligible for each race, socioeconomic, and insurance group were obtained in the weighted sample using multinomial logistic regression adjusting for age using 10-year age categories. We fit 2 multivariable models: the first adjusted for each of the other race and socioeconomic factors (race, education, and income) and the second also included insurance status. Multinomial logistic regression is used to model nominal outcome variables, in which the log odds of the outcomes are modeled as a linear combination of the predictor variables. The overall relationship between each socioeconomic factor and statin eligibility was determined to be statistically significant before calculating pairwise odds ratios. We also examined race, education, income, and insurance differences among the number of people who were eligible for statins under ATP-III guidelines but not receiving cholesterol medication. All analyses were performed using R statistical software, version 0.98.501.
Results

Study Sample
The final NHANES analytic sample included 5023 individuals and was extrapolated to the 117.6 million US adults between 40 and 75 years of age (Table 1) . Of these, 46.1 million (39.2%) were eligible for statin use under the ATP-III guidelines, and 63.6 million (54.1%) were eligible under the 2013 ACC/AHA guidelines.
Race Differences in Change in Statin Eligibility
Statin eligibility increased in all races ( 
Education Differences in Change in Statin Eligibility
Statin eligibility increased across all levels of education ( Table 1 ). The increase was greatest among individuals with less than ninth grade education (50.9%-69.1%) and least among those who completed college (32.5%-44.6%).
Of the 4 indications for statin eligibility under the 2013 ACC/AHA guidelines, the proportion of individuals eligible for elevated LDL cholesterol (≥190 mg/dL) did not differ significantly between education groups ( Figure 1 ; Table  IB in the Data Supplement). The percent eligible based on either established cardiovascular disease, diabetes mellitus, or elevated PCE risk did differ significantly. When compared with individuals who completed college, those with less than ninth grade education had higher rates of eligibility based on cardiovascular disease (14.5% versus 6.2%), diabetes mellitus (22.6% versus 7.7%), and elevated PCE risk (39.8% versus 22.3%).
Thus, expansion of statin eligibility under the 2013 ACC/ AHA guidelines differed significantly by education (Table 1 ; Figure 2 ). In a fully adjusted model, the odds of becoming eligible for statins were 1.7× higher for individuals with no more than high school education (P<0.001) compared with individuals who completed college ( Figure 2 ; Table II in the Data Supplement). No more than 1.3% of individuals in different education categories lost eligibility under the 2013 ACC/AHA guidelines, with no significant differences between the groups (Table III in the Data Supplement).
Income Differences in Change in Statin Eligibility
Statin eligibility increased across all levels of income ( Table 1 ). The increase was greater among individuals in the lowest income quartile (49.9%-67.1%) and less marked among those in the highest income quartile (36.4%-47.6%).
Of the 4 indications for statin eligibility under the 2013 ACC/AHA guidelines, the proportion of individuals eligible for elevated LDL cholesterol (≥190 mg/dL) did not differ significantly between income groups ( Figure 1 ; Table  IC in the Data Supplement). The percent eligible based on either established cardiovascular disease, diabetes mellitus, or elevated PCE risk did differ significantly. When compared with individuals in the highest income quartile, those in the lowest quartile had higher rates of eligibility based on cardiovascular disease (17.1% versus 6.6%), diabetes mellitus (18.0% versus 8.0%), and elevated PCE risk (40.0% versus 24.2%). Extrapolation from NHANES sample to US population. N is in millions. Significance testing was performed across race, education, income, and insurance categories using χ 2 tests. ACC/AHA indicates American College of Cardiology/American Heart Association guideline on the treatment of cholesterol; ATP-III, third adult treatment panel of the National Cholesterol Education Program; and NHANES, National Health and Nutrition Examination Surveys.
The expansion of statin eligibility under the 2013 ACC/ AHA guidelines differed significantly by income in unadjusted comparisons but not after adjusting for age, race, and education ( Figure 2 ; Table II 
Differences in Statin Eligibility by Race, Education, and Income
Race differences in statin eligibility were not significant under the ATP-III guidelines but were more pronounced and significant under the 2013 ACC/AHA guidelines (Table 1) . Education and income differences were significant under the ATP-III guidelines. However, they were markedly more pronounced under the 2013 ACC/AHA guidelines (Table 1) , with 69.1% of those with less than ninth grade education eligible compared with 44.6% who completed college and 67.1% eligible in the lowest income quartile compared with 47.6% in the highest quartile.
Race, Education, and Income Differences in Cardiovascular Risk Factors
There were race, education, and income differences in the prevalence of cardiovascular risk factors (Table 2) . Hypertension, diabetes mellitus, and obesity were more prevalent among nonwhite, less educated, and lower income groups. Current smoking was more prevalent among less-educated and lower income groups.
Health Insurance Coverage and Change in Statin Eligibility
The percentage of adults covered by health insurance was lower in nonwhite, less-educated, and lower income groups (P<0.001 across each group; Table 3 ). Statin eligibility increased more among individuals with no health insurance (33.6%-49.8%) than among individuals with health insurance (40.1%-54.8%; Table 1 ). In a fully adjusted model, the odds of becoming eligible for statins were 1.5× greater for individuals without health insurance compared with individuals with health insurance (P<0.001; Table II in the Data Supplement). Including insurance status in the model did not affect the relationship between race or socioeconomic groups and statin eligibility.
Patients Eligible Under ATP-III Criteria but Not Taking Statins
Among the adults eligible for statins under ATP-III criteria, only 59.2% reported receiving cholesterol-lowering therapy ( Table 3 ). The percentage of eligible people receiving therapy seemed lower among nonwhite adults (51.7% versus 62.4%), those with no more than high-school education (56.9% versus 64.4%), and those in the lowest 2 income quartiles (56.4% versus 64.3%) when compared with white adults and the highest socioeconomic categories. There were statistically significant differences across the categories of race and income but not education. Insurance coverage among adults eligible for statins was also lower among nonwhite, less educated, and lower income groups.
Discussion
The 2013 ACC/AHA guidelines expand statin eligibility beyond the ATP-III guidelines due primarily to a lower threshold of calculated cardiac risk and a lower minimum threshold for LDL cholesterol among diabetics. The expansion in statin eligibility is thus driven by conventional risk factors for cardiovascular disease, particularly diabetes mellitus and the inputs for cardiac risk calculation: hypertension, smoking, and cholesterol levels. Our study demonstrates that the increase in eligibility was strongly related to race and education even after adjusting for age and income, whereas income had no independent association with statin eligibility. Our data further demonstrate that there are marked differences in rates of hypertension, diabetes mellitus, and smoking among race and education groups, which underpin the asymmetrical increases in eligibility for statin therapy.
Our analysis builds on the work of Carroll et al 22 and Pencina et al 8 to provide a more complete understanding of statin use in the United States and the effect of the 2013 ACC/ AHA guidelines on the US population. We applied both the 2013 ACC/AHA and ATP-III guidelines to the same NHANES sample; thus, the observed differences in statin eligibility do not reflect changes in the population. They occur because the distribution of diabetes mellitus and the cardiac risk factors that determine PCE risk are heavily influenced by race and education. These findings are consistent with the body of literature demonstrating that cardiovascular risk factors are more prevalent among those with socioeconomic disadvantage. 23, 24 Strategies to prevent cardiovascular disease will need to take these realities into account. For prevention to succeed, care will need to be accessible and affordable for all classes of society. Yet, even now, there is evidence this is not the case. We found that insurance coverage and statin use among eligible people were lower in nonwhite, less-educated, and lower income adults. It has been well documented that nonwhites and people with lower income or education are less likely to receive treatment with cardioprotective medications in general and statins in particular. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This may be because of several factors, including lower rates of awareness about dyslipidemia, 11, 25 lower rates of prescribing appropriate medications, 13, 14, 17 poorer medication adherence, 26, 27 or poorer insurance coverage and access to care. [28] [29] [30] We found that individuals without health insurance were more likely to become newly eligible for statins, independent of race and socioeconomic effects. Being uninsured has been associated with underdiagnosis and undertreatment of dyslipidemia, diabetes mellitus, and hypertension, 31, 32 as well as increased mortality. 33, 34 Similar to our findings, previous studies have shown that nonwhite, less-educated, and lower income adults are more likely to be uninsured. 10 Thus, the 2013 ACC/AHA guidelines recommend expanding statin use most among disadvantaged groups who are the least likely to receive treatment.
Our findings suggest that application of the 2013 ACC/ AHA guidelines 5 will exacerbate treatment gaps between advantaged and disadvantaged populations. The 2013 ACC/ AHA guidelines increase the number of US adults eligible for statin therapy by ≈18.6 million. Of these, 12.4 million (66.3%) would be either nonwhite, have no more than highschool education, or be in the lower 2 income quartiles, and 3.0 million (16.1%) would be uninsured. If the existing treatment gaps for disadvantaged groups remain unchanged, the 2013 ACC/AHA guidelines would increase the number of US adults who are eligible for but do not receive statins by 3.0 million nonwhite people, 3.6 million people with no more than high school education, and 4.1 million people in the lowest 2 income quartiles.
In addition to improving health insurance coverage and access to care, there is evidence that interventions to increase statin use may be effective and that these could be implemented at the population level to address socioeconomic disparities. 35, 36 Data from the PINNACLE registry of US patients Extrapolation from NHANES sample to US population. Eligible adults defined as those who were eligible for cholesterol-lowering treatment as per third adult treatment panel of the National Cholesterol Education Program recommendations. N is in millions. The differences in percentage of individuals covered by health insurance were significant across race, education, and income groups in both the total population and among adults eligible for statins (P<0.001 for all comparisons). The differences in rates of eligible individuals receiving medication were significant across race (P<0.001) and income (P=0.05) but not across education (P=0.19) groups. NHANES indicates National Health and Nutrition Examination Surveys.
with peripheral arterial disease demonstrated that socioeconomic differences in statin prescribing were largely driven by differences in the practice site where patients received care. 16 This suggests that there is also an opportunity for providertargeted interventions to reduce disparities in medication use.
The fact that predicted PCE risk is the main driver of race differences in statin eligibility raises the important question of race in cardiac-risk prediction. An advantage of the PCE compared with the Framingham risk score is the use of a separate equation for black Americans. There is evidence that race differences in cardiovascular risk exist beyond traditional measured metabolic risk factors, 37, 38 and further work is needed to clarify whether accounting for racial differences can improve population-specific prognostication. There is a growing body of literature and some controversy about the accuracy of risk estimation using the PCE [39] [40] [41] ; however, Colantonio et al 42 found that the PCE have good calibration and discrimination among individuals with social deprivation, defined as low income, low education, or living without a partner. They also found that the PCE overestimate cardiovascular risk in individuals with less social deprivation. This suggests that future efforts to improve the calibration of the PCE may even further widen differences in treatment recommendations between advantaged and disadvantaged groups.
There are several limitations to our study. First, our analysis is based on NHANES data, and our extrapolation to the US population would be affected by the representativeness and accuracy of the NHANES sample from 2005 to 2012. Second, our analysis of people eligible but not taking statins is based on selfreport of statin use. The reliability of this data is strengthened by the NHANES method, in which prescription drug use was assessed during in-home interviews and prescription containers were seen for 84% of drugs. 43 Third, we used several approximations to determine whether patients were eligible for statin therapy. Similar to prior analyses, 8 we estimated 2 of 3 patients with heart failure had underlying coronary artery disease, and we used the NHANES data pertaining to family history of heart disease, which is angina pectoris or myocardial infarction in a first-degree relative under the age of 50 years. This is somewhat different from the definitions of 55 years in male relatives and 65 years in female relatives that is recommended in the ATP-III guidelines and could underestimate the number of people eligible for statin therapy. Fourth, 1557 participants did not have fasting bloodwork data and thus needed to be excluded. Fifth, similar to the analysis by Pencina et al, 8 we limited our analysis to adults between 40 and 75 years because the ACC/AHA guidelines make no recommendations outside this age range because of a lack of high-quality evidence. Finally, our analyses assume that statin therapy would be recommended for all individuals for whom statins are likely to have benefit. This is a simplification of the 2013 ACC/AHA guidelines, which recommend individualized shared decision making about statin treatment between patients and their physicians.
In conclusion, the 2013 ACC/AHA guidelines expand statin eligibility most among disadvantaged populations and those without health insurance, particularly Americans with nonwhite race and less education. The dissemination of the 2013 ACC/AHA guidelines represents an important opportunity to address race and socioeconomic disparities in statin prescribing. Without appropriate access to healthcare, the potential gains from expanding indications for cardioprotective medications will not be realized. In the longer term, our findings further highlight the crucial relationships between race, education, and population health.
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